Are you looking for it services & solution provider?
Debosmita Ghosh • 27 Nov 2024
Lancet Study Says GLP-1 Drugs Ozempic, Wegovy Can Be Beneficial For The Kidneys
GLP-1 Drugs Ozempic, Wegovy Can Be Beneficial For The Kidneys
A recent study showed that GLP-1 drugs which are beneficial for diabetes and weight loss can also protect your kidneys from damage. GLP-1 drugs include Ozempic which is prescribed for diabetes and Wegovy which is prescribed for Wegovy. The study was published in The Lancet Diabetes & Endocrinology.
This is the largest study which analysed the effects of the drugs on the kidneys of people with or without diabetes. Dr Sunil Badve, a kidney specialist and professorial fellow at The George Institute for Global Health in Sydney, Australia and lead author of the study said, “This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease.”
The study says that GLP-1s “have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or chronic kidney disease.”
Badve and colleagues conducted a meta-analysis of 11 large-scale clinical trials of GLP-1s involving more than 85,000 people in all. Nearly, 68,000 had type 2 diabetes while just over 17,600 were overweight or obese with heart disease but did not have type 2 diabetes.
The GLP-1 medicines taken during the trials included semaglutide (Ozempic or Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza).
The study found that kidney health improved in people taking the drugs.
The researchers found that the use of a GLP-1 reduced a patient’s risk of kidney failure by 16% and a worsening of their kidney function by 22%. These improvements were defined as “a drop in estimated glomerular filtration rate -- a measure of how much blood the kidneys filter clean every minute -- of at least 50%.”
Badve said, “These results are particularly important for patients with chronic kidney disease. It is a progressive condition eventually leading to kidney failure requiring dialysis or kidney transplantation and is associated with premature death, mostly from heart disease. It has a significant impact on patients’ quality of life and incurs substantial healthcare costs.”
The study also revealed that the use of GLP-1 drugs was linked to a 13% reduction in a person’s risk of premature death from any cause. These drugs are beneficial for heart health as well. -1 cuts an individual’s risks for a combination outcome of heart-related death, non-fatal heart attacks and non-fatal strokes by 14%, compared to folks taking a placebo.
Dr Vlado Perkovic, also a professorial fellow at The George Institute and co-author of the study said, “Our study will have a major impact on clinical guidelines for the management of chronic kidney disease and cardiovascular disease in people with and without diabetes.”
Get Latest News Live on Times Now along with Breaking News and Top Headlines from Health and around the world.